Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study i
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
04:30pm, Wednesday, 01'st May 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after mar
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
10:02am, Wednesday, 24'th Apr 2024
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytol
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
08:30am, Monday, 08'th Apr 2024
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion �
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
08:14pm, Wednesday, 20'th Mar 2024
CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall respons
Why Coherus Biosciences Stock Tumbled on Thursday
06:28pm, Thursday, 14'th Mar 2024
The biotech unveiled its latest set of quarterly and annual results. Its revenue for the former period rose sharply, but missed analyst expectations -- as did its bottom-line result.
Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript
08:56pm, Wednesday, 13'th Mar 2024
Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
04:01pm, Wednesday, 13'th Mar 2024
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERL
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
04:01pm, Tuesday, 05'th Mar 2024
REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be r
Coherus Completes Divestiture of Ophthalmology Franchise
01:00am, Monday, 04'th Mar 2024
– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus' strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) --
Coherus BioSciences Announces New Employment Inducement Grants
05:33pm, Friday, 23'rd Feb 2024
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
08:30am, Wednesday, 21'st Feb 2024
– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receivi
Why Coherus BioSciences Stock Jumped Today
05:16pm, Tuesday, 06'th Feb 2024
Following the closing of its recently announced divestiture of its noncore ophthalmology business, Coherus will prepay a huge chunk of its term loan with Pharmakon. The move will reduce interest expen
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
08:00am, Monday, 05'th Feb 2024
- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be reduce
Why Coherus BioSciences Stock Is Sinking Today
11:37am, Tuesday, 23'rd Jan 2024
Coherus BioSciences stock initially jumped after the announcement of a deal to sell Cimerli to Sandoz. However, shares are now sinking with investors reminded of the financial challenges that Coherus
